Printer Friendly
The Free Library
14,669,765 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Health Enhancement Products Announces Commencement of HIV And CRP Clinical Trials in Cameroon.


SCOTTSDALE, Ariz. -- Health Enhancement Products Inc., (OTCBB OTCBB

See OTC Bulletin Board (OTCBB).
:HEPI HEPI Higher Education Price Index
HEPI Heavy Equipment Point of Impact (military paradrop)
HEPI High Explosive Penetrating Incendiary
) announced today that the HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States.  clinical trials for HEPI's ProAlgaZyme product, recently approved to be conducted in Cameroon, commenced on Friday, May 19, 2006. The trial will explore ProAlgaZyme's (PAZ Paz   , Octavio 1914-1998.

Mexican writer whose essays, including The Labyrinth of Solitude (1950), and volumes of poetry, such as Sun Stone (1957), often explore the Mexican identity. He won the 1990 Nobel Prize for literature.
) potential to reduce viral loads in patients with HIV. The trial calls for 70 participants and is expected to be completed in 60 days. An additional study to investigate PAZ's potential effects on C-Reactive Protein C-Reactive Protein Definition

C-reactive protein (CRP) is a protein produced by the liver and found in the blood.
Purpose

C-reactive protein is not normally found in the blood of healthy people.
 (CRP C-reactive protein (CRP)
A protein present in blood serum in various abnormal states, like inflammation.

Mentioned in: Pelvic Inflammatory Disease

CRP,
n.pr See C-reactive protein.
) levels and the inflammation process have also begun. The double blind CRP study calls for 40 participants and should also be completed in 60 days. Both studies are being conducted by Dr. Julius E. Oben, head of the Department of Biochemistry, University of Yaounde in Cameroon and have been approved by the University Teaching Hospital Review Board, the Cameroon National Ethics Committee ethics committee A multidisciplinary hospital body composed of a broad spectrum of personnel–eg, physicians, nurses, social workers, priests, and others, which addresses the moral and ethical issues within the hospital. See DNR, Institutional review board. , and the Cameroon Ministry of Health.

Howard R. Baer, Founder and Chairman of Health Enhancement Products, stated, "It has been 10 years of trials and tribulation, anxiety and excitement working with this product, and, so far, I've never been disappointed with any of our test results. I don't expect to be disappointed this time either. While I'm sure this will be the longest 60 days of my life, I'm optimistic that there will be some celebrating when the results are in. If the HIV trials come out as we anticipate they will, it could be a major breakthrough for the HIV community."

Approximately 38 million people worldwide are living with HIV, about 65% of whom (25 million) are living in Sub-Saharan Africa, the region of Africa where the University of Yaounde, Cameroon, is located. Considering the extremely high rate of HIV incidents in the region, HEPI determined that Cameroon would be an ideal place to conduct the HIV clinical trials.

About Health Enhancement Products Inc.

Health Enhancement Products Inc. is a nutraceutical company engaged in the development of a supplementary health-enhancing product using only pure, all-natural ingredients. The company's sole product is ProAlgaZyme, a phytopercolate that is produced from an algae algae (ăl`jē) [plural of Lat. alga=seaweed], a large and diverse group of primarily aquatic plantlike organisms. These organisms were previously classified as a primitive subkingdom of the plant kingdom, the thallophytes (plants that  grown in 100% distilled water Noun 1. distilled water - water that has been purified by distillation
H2O, water - binary compound that occurs at room temperature as a clear colorless odorless tasteless liquid; freezes into ice below 0 degrees centigrade and boils above 100 degrees centigrade;
.

The algae from which ProAlgaZyme is derived produces a protein, most likely as a means of protecting itself from exposure to outside disease and harmful bacteria. The protein solution is then drawn off, filtered, tested and bottled for consumption. In addition to supporting a compromised immune system immune system

Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders.
, recent clinical studies indicate that ProAlgaZyme has potential weight loss properties. ProAlgaZyme has also been shown in a clinical study to have the potential to improve serum glucose management, when combined with a diet low in refined carbohydrates and a light exercise regimen.

For more information, please visit www.heponline.com.

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including clinical trial results being different than the company's anecdotal results and the company's ability to fund its operations and market and sell its ProAlgaZyme product. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:May 22, 2006
Words:589
Previous Article:Transera(TM) Communications Named a Red Herring 100 Winner; Award Recognizes the 100 Private Technology Firms in North America Driving the Future of...
Next Article:Point of Sale (POS) Systems with mModule uDOC from msystems(TM) Realize Benefits of Smarter Storage; Integrating msystems' mModule uDOC Product,...
Topics:



Related Articles
New strain of HIV appears in Cameroon.(Brief Article)
Uncle Sam wants you. Federal HIV research finally comes to Houston.
HIV-1 Group O Infection in Cameroon, 1986-1998.(Statistical Data Included)
SMART: background, concepts, and design.(research on long-term effects of highly active antiretroviral therapy)
Time to get SMART.(research on long-term effects of antiretroviral therapy)
The acute infection and early disease research program. (Government Research).
Clinical use of C-reactive protein for cardiovascular disease.(Review Article)
Commercial logging and HIV epidemic, rural Equatorial Africa.(Dispatches)
Central African hunters exposed to simian immunodeficiency virus.(DISPATCHES)
Antiretroviral drug resistance and routine therapy, Cameroon.(DISPATCHES)(infectious diseases research)(includes statistical table)

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles